Home > Partnerships

Partnerships

Anaxomics is looking for partners active in R&D in the fields of:
Biomarker discovery
Predictive Medicine, including Predictive Efficacy and Predictive Safety of drugs
New Target and Drug Discovery
Drug Reprofiling

We wish to collaborate with multinational R&D consortiums, both in Europe or Globally, where we can contribute:
A comprehensive Systems Biology approach for raising hypothesis and analyzing results
Technologies and perspectives perfectly aligned with strategic pillars of public initiatives (like the
ones from the Innovative Medicines Initiative)
Extensive experience in the management of public-private research consortiumsFor example, we are currently looking for partners for participating in the European VII Frame Program (including the
Innovative Medicines Initiative), or in programs like Canadeka.

For more information, please contact us here

Anaxomics launches the Global Collaborative Initiative for Drug Reprofiling. We are supporting biopharma companies to analyze and identify new indications for drugs already in the pipeline from
a rational and highly predictive perspective, on a fee-for-service, or risk-sharing basis.

Learn more about Global Drug Reprofiling

Anaxomics wishes to establish long-term partnerships with consultancy firms and other companies specialized in the Discovery / Preclinical stages of Drug Development, both in Europe and in the US. We have already established a partnership with IRIDESSA, a Swiss Company providing drug development consulting services spanning from discovery through to early proof-of-concept studies.

Iridessa

Iridessa provides drug development consulting services spanning from discovery through to early proof-of-concept studies. We work in collaboration with clients to ensure enhanced drug development decision making with the potential for faster time to market and/or lower development costs. The primary goals of the collaboration with Iridessa typically involve one or more of the following:

to optimize the design and execution of development program(s) for one or more candidate therapeutic agent(s)
to facilitate out / in-licensing discussions with potential business partners
to support ongoing interactions with regulatory authorities

Iridessa provides clinical safety consulting services focused on preclinical and phase I safety issues. Our services will help you to detect and resolve preclinical and early clinical safety issues in a timely and cost-effective manner. The principal deliverables of the safety consulting engagement with Iridessa are:

development strategy to optimally detect the specific safety issue(s)
related strategy to facilitate interactions with relevant regulatory authorities

For more information about IRIDESSA please contact Mr Georges Jaccard:
E-mail: gjaccard@iridessa.ch
Phone: +41 217 995 520
Fax: +41 217 995 521

DynaKin

DynaKin is a biopharmaceutical CRO (Contract Research Organization) addressing drug development issues across two dimensions, GLP Bioanalysis and Model (and simulation) Based Drug Development (MBDD) decision making with our DMC group.

The company has extensive knowledge in performing and in the R&D for drug development from pre-clinical, FTIM, and Phase I up to Phase III and IV clinical trials.

For more information about DYNAKIN:
Web: dynakin.com
E-mail: nleal@dynakin.com
Phone: +34 94 404 5504
Fax: +34 94 655 9463

Please, contact us here to request more information.